

1 **Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute**  
2 **respiratory illness**

3 Caitriona Murphy<sup>1</sup>, Loretta Mak<sup>1</sup>, Samuel M. S. Cheng<sup>1</sup>, Gigi Y. Z. Liu<sup>1</sup>, Alan M. C. Chun<sup>1</sup>,  
4 Katy K. Y. Leung<sup>1</sup>, Natalie Y. W. Sum<sup>1</sup>, Eero Poukka<sup>2,3</sup>, Malik Peiris<sup>1,4</sup>, Benjamin J.  
5 Cowling<sup>1,5</sup>

6  
7 **Affiliations**

8 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of  
9 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong  
10 Special Administrative Region, China

11 2. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish  
12 Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland

13 3. Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu  
14 4, 00100 Helsinki, Finland

15 4. Centre for Immunology & Infection, Hong Kong Science and Technology Park, New  
16 Territories, Hong Kong Special Administrative Region, China

17 5. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology  
18 Park, New Territories, Hong Kong Special Administrative Region, China

19

20 Corresponding author: [bcowling@hku.hk](mailto:bcowling@hku.hk)

21

22 Key words: rapid antigen test; lateral flow assay; sensitivity; specificity; influenza; COVID-  
23 19; RSV

24 Word count (abstract): 200

25 Word count (main text): 2,382

26 **ABSTRACT**

27 **Background:** We assessed the performance of three different multiplex lateral flow assays  
28 which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

29 **Methods:** Ambulatory patients 6 months and older presenting with two or more symptoms or  
30 signs of an acute respiratory illness were enrolled in an outpatient clinic in Hong Kong.

31 Multiplex lateral flow tests manufactured by SureScreen, Microprofit and Goldsite were  
32 performed by trained research staff using the nasal swabs from each test kit, and separate  
33 swabs were collected for RT-PCR testing.

34 **Results:** Between 4 April and 20 October 2023, 1646 patients were enrolled and tested by at  
35 least one lateral flow test. The point estimates for all three multiplex tests had high sensitivity  
36 above 80% for influenza A and SARS-CoV-2, and the tests manufactured by Microprofit and  
37 Goldsite had sensitivity exceeding 84% to detect RSV. Test sensitivity increased with viral  
38 load. Specificity was higher than 97% for all three tests except for the SureScreen test which  
39 had specificity 86.2% (95% CI: 83.9% to 88.3%) for influenza A.

40 **Conclusions:** The multiplex lateral flow tests provided timely diagnosis of influenza, RSV  
41 and SARS-CoV-2 infection and can be used to inform clinical management and infection  
42 control such as isolation behaviours.

43

44 **INTRODUCTION**

45 Timely and accurate diagnosis of infection from respiratory viruses is essential for managing  
46 clinical care and reducing transmission. Lateral flow tests, also referred to as rapid antigen  
47 tests, are point of care devices that can identify the presence of an infectious disease by  
48 detecting microbial proteins within 30 minutes. The key advantage of lateral flow tests over  
49 the current gold standard, polymerase chain reaction (PCR) assay is the lower cost and the  
50 quick turnaround time for results. Additionally, performing PCR tests requires trained staff  
51 and laboratory infrastructure that is resource intensive and may not always be available.  
52 Lateral flow tests were widely distributed during the COVID-19 pandemic to improve  
53 diagnosis of cases in the community and facilitate more efficient isolation and quarantine  
54 policies. The use of lateral flow tests were deemed a successful strategy in multiple locations  
55 for use in the community [1-3] and subgroups of the community where repeated testing using  
56 lateral flow tests was utilised to help keep schools and workplaces open [4-7].

57

58 In some locations, lateral flow tests are now available for detecting influenza A/B, SARS-  
59 CoV-2 and RSV in a single test kit. Diagnostic tests that can quickly identify the presence of  
60 infection while also indicating which respiratory virus an individual is infected with will aid  
61 patient management, particularly when specific antivirals should be administered rapidly  
62 after symptom onset. The turnaround time of lateral flow tests allows patients to receive  
63 appropriate antiviral treatment in a timely manner and when it may be most beneficial during  
64 the course of infection. The objective of this study was to assess the performance of three  
65 different multiplex lateral flow tests for detecting SAR-CoV-2, influenza A/B and RSV  
66 compared to RT-PCR in an outpatient setting in Hong Kong.

67

68 **METHODS**

69 *Study participants*

70 This study included outpatients enrolled in an ongoing influenza vaccine effectiveness study  
71 in Hong Kong. Patients at least 6 months of age were enrolled if they presented with acute  
72 respiratory illness defined as having at least two of seven signs/symptoms (fever  $\geq 37.8^{\circ}\text{C}$ ,  
73 cough, sore throat, runny nose, headache, myalgia and phlegm) within 72 hours of symptoms  
74 onset. Participants or their legal guardians were provided with a questionnaire to obtain  
75 demographic details as well as vaccination history.

76

77 *Rapid test procedures*

78 Upon obtaining informed consent, two lateral flow assays namely “Fluorecare SARS-CoV-2  
79 & Influenza A/B & RSV Antigen Combo Test Kit (Self-Test)” (Shenzhen Microprofit  
80 Biotech Co. Ltd., Shenzhen, China) and “SARS-CoV-2 + Flu A&B Antigen Combo Rapid  
81 Test Cassette (Nasal Swab)” (SureScreen Diagnostics Ltd, Derby, UK) were administered by  
82 the research team. If either of these tests were unavailable at the time of participant enrolment  
83 a third test, “SARS-CoV-2 & Influenza A/B & RSV Antigen Kit” (Colloidal Gold) (Goldsite  
84 Diagnostics Inc., Shenzhen, China) was used. Throughout the paper, the three multiplex  
85 lateral flow tests are named after their manufacturer, Microprofit, SureScreen and Goldsite  
86 respectively.

87

88 The Microprofit and Goldsite tests are combination tests for detecting SARS-CoV-2,  
89 influenza A/B and RSV, while SureScreen detects SARS-CoV-2 and influenza A/B. All three  
90 tests use a nasal swab and provide results within 15 minutes. Further details of the test  
91 specifications are available in the Supplementary (Supp. Table 1; Figures 1 to 3). In the event  
92 that a lateral flow tests result was invalid (i.e. there was no visible coloured band for the

93 control line) a second test was conducted but not a third test if the second was also invalid.

94 Those that had a third invalid test result were removed from the analysis.

95

### 96 ***Laboratory testing***

97 A separate set of nose and throat swabs were also collected by the research team or attending

98 physician and were pooled into a single vial of transport medium and transported to the

99 laboratory for testing. All samples were tested by reverse transcription-polymerase chain

100 reaction (RT-PCR) for influenza (A and B) and SARS-CoV-2. Moreover, all lateral flow test

101 RSV-positive and a randomly selected subset of lateral flow test RSV-negative samples were

102 tested for RSV using RT-PCR.

103

104 A standard 20  $\mu$ L RT-PCR assay was performed, comprising 5  $\mu$ L of a 4X master reaction

105 mixture (TaqMan Fast Virus 1-Step Master Mix, ThermoFisher), 0.5  $\mu$ M of the forward

106 primer, 0.5  $\mu$ M of the reverse primer, 0.25  $\mu$ M of the probe, and 2  $\mu$ L of the RNA

107 sample. The RT-PCR reactions were carried out using a ViiA7 Real-Time PCR system

108 (ThermoFisher) with the following thermal cycling conditions: reverse transcription at 50°C

109 for 5 minutes, inactivation of reverse transcriptase at 95°C for 20 seconds, followed by 40

110 cycles of PCR amplification (denaturation at 95°C for 5 seconds, annealing/extension at

111 58°C for Influenza A and B, SARS-CoV-2, 50°C for RSV A and B for 30 seconds). Primer

112 and probe sequences can be found in Supplementary Table 2. The Ct-value was evaluated

113 from all the PCR positive samples. A false-positive result was defined as a positive result for

114 a particular virus on a lateral flow test and a subsequent negative confirmatory RT-PCR result

115 for that virus.

116

117 ***Statistical analysis***

118 The sensitivity and specificity of each of the lateral flow tests was estimated using RT-PCR  
119 confirmed infection for each virus as the comparator. The incidence of influenza B was low  
120 during the study period and therefore, the performance of lateral flow tests for detecting  
121 influenza B was not evaluated. Multivariable logistic regression, including the RT-PCR  
122 positives was used to evaluate the relationship between lateral flow test positivity and age,  
123 sex, vaccination status and symptom onset. Positive and negative predictive values (PPV and  
124 NPV) were estimated conditional on different values for the true prevalence. Confidence  
125 intervals (CI) were estimated using binomial distributions. All statistical analyses were  
126 conducted using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).  
127

128 ***Ethical approval***

129 The study protocol was approved by the Institutional Review Board of the University of  
130 Hong Kong. The lateral flow tests aided with clinical management, and written informed  
131 consent was obtained for each participant and parental consent was obtained for participants  
132 below 18 years of age.

133

134 **RESULTS**

135 Between 4 April and 20 October 2023, 1646 outpatients with acute respiratory symptoms  
136 were enrolled. Males accounted for 47.0% and 63.3% were children (<18 years old). The  
137 majority (26.3%) of adults were less than 50 years old with just 4.1% being 65 years of age or  
138 older. All patients were tested for influenza and SARS-CoV-2 by RT-PCR. Influenza A was  
139 detected in 651 (39.6%) patients and 171 (10.4%) were laboratory confirmed SARS-CoV-2.  
140 During our study period the predominant SARS-CoV-2 strains in the community were  
141 Omicron XBB subvariants. Of the 431 samples tested for RSV by RT-PCR 75 (17.4%) were

142 positive. The Microprofit test was used to test 814 (49.5%) patients, and 832 (50.5%) were  
143 tested using the Goldsite test. SureScreen was performed by 1632 (99.1%) patients and the  
144 reasons for not being tested for the remaining 23 patients were because the test was out of  
145 stock (7/23), they were not feeling well (6/23), were too busy (3/23) or other unspecified  
146 reasons (7/23).

147

148 The SureScreen test had a significantly higher sensitivity (89.7%, 95% CI: 87.0% to 91.9%)  
149 compared to Microprofit (82.1%, 95% CI: 77.0% to 86.5%) and Goldsite (84.9%, 95% CI:  
150 80.9% to 88.3%) for detecting influenza A but performed similarly for detecting SARS-CoV-  
151 2. Both the Microprofit and Goldsite tests were comparable for detecting RSV (Table 1). This  
152 is reflected in the NPV estimates for different values of prevalence in Figure 1. When the  
153 viral load was high (i.e. low CT value) all three tests had a higher sensitivity compared to  
154 patients with low viral loads particularly for detecting influenza A and SARS-CoV-2. The  
155 sensitivity ranged from 87.5% to 100% for detecting CT values <25 and from 28.6% to  
156 75.0% for detecting CT values  $\geq 30$  (Figure 2). Microprofit and SureScreen had a  
157 significantly lower sensitivity among those 65 years and older compared to younger age  
158 groups for detecting influenza A (Supp. Table 2; Figure 4). Sensitivity for those 65 years and  
159 older was 25.0% (95% CI: 3.2% to 65.1%) and 70.8% (95% CI: 48.9% to 87.4%) compared  
160 to 86.3% (95% CI: 73.7% to 94.3%) and 94.6% (95% CI: 88.7% to 98.0%) for those 6  
161 months to 5 years old for Microprofit and SureScreen respectively. Lateral flow tests were  
162 more sensitive for detecting influenza A in patients with a symptom onset between 1 to 2  
163 days prior to presentation (odds ratio: 1.2, 95% CI: 1.1 to 4.7) compared to those with  
164 symptom onset within 1 day. The estimates of test sensitivity for patients that were  
165 vaccinated for influenza and COVID-19 were similar to those who had not been vaccinated  
166 for the respective pathogen (Supp. Table 3).

167

168 Specificity for the Microprofit and Goldsite tests were significantly higher than SureScreen  
169 for detecting both influenza A and SARS-CoV-2, resulting in a lower PPV for SureScreen  
170 (Figure 1). Other than the lower specificity for SureScreen for detecting influenza A (86.2%,  
171 95% CI: 83.9% to 88.3%), the remaining test and virus specific point estimates had a  
172 specificity over 97% (Table 1). Specificity was similar across age groups and vaccination  
173 status. Among the 138 influenza A false positives 8 (5.8%) were laboratory confirmed  
174 SARS-CoV-2 infections and among the SARS-CoV-2 false positives (n=30) and RSV false  
175 positives (n=5) there were 3 patients among each that tested positive for influenza A by RT-  
176 PCR (Supp. Table 4).

177

## 178 **DISCUSSION**

179 We evaluated the performance of three multiplex rapid tests, Microprofit, Goldsite and  
180 SureScreen in symptomatic individuals in an ambulatory care setting in Hong Kong  
181 compared to the gold standard of RT-PCR. Point estimates of Microprofit and Goldsite tests  
182 reached the WHO minimum test performance for all three viruses with a sensitivity of  $\geq 80\%$   
183 and specificity  $\geq 97\%$  [8]. SureScreen did not meet these requirements for all targeted  
184 respiratory viruses in a single test kit. Instead it had a high sensitivity for detecting influenza  
185 A and SARS-CoV-2 but had a lower specificity for detecting influenza A (86.2%, 95% CI:  
186 83.9% to 88.3%). The study period was during the seasonal influenza epidemic in Hong  
187 Kong, with one epidemic peak in late April dominated by influenza A(H1N1) and a second  
188 peak in September dominated by influenza A(H3N2) [9]. An epidemic of SARS-CoV-2,  
189 dominated by Omicron XBB subvariants also occurred from April to July 2023 [9] and  
190 therefore, we expected the resulting PPV and NPV during periods of higher prevalence to be  
191 moderate to high.



192

193 The estimates in this study are higher than those observed in some previous studies [10-15].

194 Although, studies estimating the performance of the same tests as those evaluated here were

195 among asymptomatic individuals and we were unable to find studies using the same

196 multiplex tests among symptomatic individuals. The varying sensitivity for symptomatic and

197 asymptomatic individuals has been documented [16] but a systematic review also identified

198 that the performance of lateral flow tests in symptomatic individuals had a wide range (34.3%

199 to 91.3%) depending on the manufacturer [16]. We identified one study estimating the

200 performance of a multiplex Microprofit test that reported a sensitivity for detecting influenza

201 A of 80.8% (95% CI: 67.2% to 94.4%) among asymptomatic individuals. However, the test

202 sensitivity was 41.5% (95% CI: 26.2% to 56.8%) for detecting RSV in that study [12]

203 compared to 94.6% (95% CI: 81.8% to 99.3%) estimated in this study. The performance of a

204 singleplex SureScreen test for detecting SARS-CoV-2 was evaluated in inpatients and

205 outpatients from a single centre in the UK with a lower estimated sensitivity of 65% (95% CI:

206 55.2% to 73.6%) but a very high specificity at 100% (95% CI: 96.3% to 100%) [10]. Another

207 study using a singleplex SureScreen diagnostic test to detect SARS-CoV-2 estimated a

208 sensitivity and specificity of 28.8% (95 CI%: 20.2% to 38.6%) and 97.8% (95% CI: 94.5%

209 to 99.4%) respectively for mass screening in unexposed asymptomatic individuals [11].

210 Compared to the sensitivity and specificity estimates reported by the manufacturers

211 (Appendix Table 1), our study estimates, in a real-world context, were slightly lower.

212

213 The estimated sensitivity of the three lateral flow tests increased as the viral load increased

214 which is consistent with previous literature [17-20]. Some studies suggest that the viral load

215 is higher in patients with more severe outcomes, especially considering severe cases might

216 take longer to clear infection [21]. In turn, if the sensitivity is higher for detecting severe

217 cases, the use of lateral flow tests could support timely prescription of antivirals. A lower  
218 sensitivity for those with a lower viral load could have negative implications when  
219 implementing lateral flow tests. Of the 88 false negatives in this study, 76% had lower viral  
220 loads. Falsely testing negative may lead to a failure to isolate and a missed opportunity to  
221 reduce onwards transmission, albeit this typically occurred among individuals with lower Ct  
222 values who might perhaps be less contagious. Health authorities in Hong Kong currently  
223 recommend symptomatic individuals use a lateral flow test and for those who test negative it  
224 is recommended to remain cautious and repeat the test over a few days [22].

225

226 Our evaluation of lateral flow test performance has limitations. While RT-PCR is often  
227 considered a gold standard it can detect inactive virions for a few weeks after infection [23].  
228 An overestimate of infections identified by RT-PCR may subsequently underestimate the  
229 sensitivity of lateral flow tests if the objective is to identify contagious individuals and  
230 individuals early in their course of disease when antivirals would be more effective and  
231 transmission-reducing measures such as isolation could be implemented more effectively.  
232 Data were collected prospectively based on the presence of symptoms and with symptom  
233 onset occurring within three days and therefore there was a smaller sample of patients with Ct  
234 values >30, particularly for RSV. Viral culture was not carried out in this study to confirm  
235 the relationship between infectiousness and testing positive by lateral flow tests. Finally, the  
236 sensitivity may vary depending on the strains of SARS-CoV-2 circulating which in our study  
237 period included Omicron XBB subvariants. The SureScreen test evaluated here target the  
238 more conserved nucleocapsid protein of SARS-CoV-2 (as opposed to the spike protein),  
239 however variation in the test performance may persist across virus lineages [14]. It was  
240 unclear which SARS-CoV-2 protein Microprofit and Goldsite targeted.

241

242 To conclude, each of the three evaluated multiplex tests performed well in detecting one of  
243 the viral antigens in the multiplex lateral flow test but necessarily all targeted respiratory  
244 viruses. The use of lateral flow tests has been more limited in healthcare settings where PCR  
245 is readily available. However, they can efficiently implement control measures and providing  
246 an accurate diagnosis will guide appropriate treatment.

247

248

249 **ACKNOWLEDGMENTS**

250 The authors thank Julie Au for technical support. This research was supported by the Health  
251 and Medical Research Fund, Health Bureau, The Government of the Hong Kong Special  
252 Administrative Region (grant no. INF-HKU-3). BJC is supported by the Theme-based  
253 Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong  
254 Kong SAR Government.

255

256 **POTENTIAL CONFLICTS OF INTEREST**

257 BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer,  
258 Roche, and Sanofi Pasteur. The authors report no other potential conflicts of interest.

259

260

261

## REFERENCES

1. Pavelka M, Van-Zandvoort K, Abbott S, et al. The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia. *Science* **2021**;372(6542):635-41.
2. Ferrari D, Stillman S, Tonin M. Assessing the impact of COVID-19 mass testing in South Tyrol using a semi-parametric growth model. *Sci Rep* **2022**;12(1):17952.
3. Hodges E, Lefferts B, Bates E, et al. Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities - Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020-March 1, 2021. *MMWR Morb Mortal Wkly Rep* **2021**;70(33):1120-3.
4. Dewald F, Suarez I, Johnen R, et al. Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children. *Nat Commun* **2022**;13(1):3640.
5. Mendoza RP, Bi C, Cheng HT, et al. Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities. *EClinicalMedicine* **2021**;38:101028.
6. Leng T, Hill EM, Holmes A, et al. Quantifying pupil-to-pupil SARS-CoV-2 transmission and the impact of lateral flow testing in English secondary schools. *Nat Commun* **2022**;13(1):1106.
7. Gorji H, Lunati I, Rudolf F, et al. Results from Canton Grisons of Switzerland suggest repetitive testing reduces SARS-CoV-2 incidence (February-March 2021). *Sci Rep* **2022**;12(1):19538.
8. The World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. Interim Guidance. **2021**. (<https://iris.who.int/bitstream/handle/10665/345948/WHO-2019-nCoV-Antigen-Detection-2021.1-eng.pdf?sequence=1>). (Accessed 11 Mar 2024).
9. The Centre for Health Protection. COVID-19 & FLU EXPRESS. **2023**;1(39):1-19.

10. Pickering S, Batra R, Merrick B, et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. *Lancet Microbe* **2021**;2(9):e461-e71.
11. Baro B, Rodo P, Ouchi D, et al. Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. *J Infect* **2021**;82(6):269-75.
12. Bayart JL, Gillot C, Dogne JM, et al. Clinical performance evaluation of the Fluorecare(R) SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals. *J Clin Virol* **2023**;161:105419.
13. Tonelotto V, Davini A, Cardarelli L, et al. Efficacy of Fluorecare SARS-CoV-2 Spike Protein Test Kit for SARS-CoV-2 detection in nasopharyngeal samples of 121 individuals working in a manufacturing company. *PLoS One* **2022**;17(1):e0262174.
14. Bown A, Sweed A, Catton M, et al. Detection of SARS-CoV-2 BA.2.86 by lateral flow devices. *Int J Infect Dis* **2024**;139:168-70.
15. Salvagno GL, Gianfilippi G, Pighi L, et al. Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit. *Adv Lab Med* **2021**;2(3):409-16.
16. Dinnes J, Sharma P, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev* **2022**;7(7):CD013705.
17. Eyre DW, Futschik M, Tunkel S, et al. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study. *Lancet Infect Dis* **2023**;23(8):922-32.
18. Fernandez-Montero A, Argemi J, Rodriguez JA, et al. Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values. *EClinicalMedicine* **2021**;37:100954.

19. Lefever S, Indevuyst C, Cuypers L, et al. Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients. *J Clin Microbiol* **2021**;59(7):e0037421.
20. Bond KA, Smith B, Gardiner E, et al. Utility of SARS-CoV-2 rapid antigen testing for patient triage in the emergency department: A clinical implementation study in Melbourne, Australia. *Lancet Reg Health West Pac* **2022**;25:100486.
21. Lin Y, Wu P, Tsang TK, et al. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study. *Lancet Microbe* **2023**;4(9):e722-e31.
22. The Government of the Hong Kong Special Administrative Region. Rapid Antigen Tests. **2024**. (<https://www.coronavirus.gov.hk/eng/rat.html#:~:text=An%20RAT%20is%20designed%20to,or%20deep%20throat%20saliva%20samples.>). (Accessed 22 Feb 2024).
23. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro Surveill* **2020**;25(32).

## TABLES

Table 1: The performance of lateral flow tests for detecting influenza A, SARS-CoV-2 and RSV infection.

Respiratory virus and test manufacturer	Sensitivity		Specificity	
	%	95% CI	%	95% CI
<b>Influenza A</b>				
Microprofit	82.1	77.0 to 86.5	97.6	95.9 to 98.7
Goldsite	84.9	80.9 to 88.3	98.0	96.2 to 99.1
SureScreen	89.7	87.0 to 91.9	86.2	83.9 to 88.3
<b>SARS-CoV-2</b>				
Microprofit	81.7	73.5 to 88.3	99.4	98.5 to 99.8
Goldsite	80.4	67.6 to 89.8	99.4	98.5 to 99.8
SureScreen	88.2	82.3 to 92.6	98.1	97.2 to 98.7
<b>RSV*</b>				
Microprofit	94.6	81.8 to 99.3	97.6	94.1 to 99.4
Goldsite	84.2	68.7 to 94.0	99.5	97.1 to 100

\*The SureScreen test did not include RSV



## FIGURE LEGENDS




Figure 1: Relationship between the positive and negative predictive values and prevalence for each test. Predictive values were estimated using the sensitivity and specificity presented in Table 1. The specificity for Microprofit and Goldsite were the same for detecting SARS-CoV-2 and the SureScreen test did not include RSV. The shaded areas represent the 95%

confidence intervals and the prevalence of each respiratory virus, during the study period, are represented by the grey boxplots.




Figure 2: Sensitivity with 95% confidence intervals of each lateral flow test by Ct value category.

